Cost-effectiveness analysis of oxaliplatin/5-fu/lv in adjuvant treatment of stage III colon cancer in the UK and Germany

被引：0
|
作者：
Aballea, S
Chancellor, J
Raikou, M
Drummond, M
Diel, R
Frick, M
Rosenfeld, S
Boler, A
Jourdan, S
Paulo, C
Bridgewater, J
机构：
[1] Innovus Res UK Ltd, High Wycombe, Bucks, England
[2] London Sch Econ, London, England
[3] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[4] Aventis Pharma Deutschland GmbH, Berlin, Germany
[5] Heron Evidence Dev, Letchworth Garden City, England
[6] Sanofi Aventis R&D, Bagneux, France
[7] UCL Royal Free & Univ Coll Med Sch, London, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67203-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A21 / A21
页数：1
相关论文
共 50 条
  • [41] Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals
    Pumpalova, Yoanna
    Rogers, Alexandra M.
    Tan, Sarah Xinhui
    Herbst, Candice-lee
    Ruff, Paul
    Neugut, Alfred I.
    Hur, Chin
    JCO GLOBAL ONCOLOGY, 2021, 7 : 1730 - 1741
  • [42] Incomplete 5-FU based adjuvant chemotherapy in patients with stage III colon cancer significantly prolongs overall survival
    Hoffmann, Martin
    Ogbonnaya, Lucky
    Benecke, Claudia
    Braun, Ruediger
    Zimmermann, Markus
    Schloericke, Erik
    Keck, Tobias
    INTERNATIONAL JOURNAL OF SURGERY OPEN, 2018, 14 : 19 - 26
  • [43] Cost-effectiveness of adjuvant therapy for treatment of stage II colon cancer in patients with diabetes.
    Dinh, T.
    Alperin, P.
    O'Neil, B. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [44] Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).
    Diaz-Rubio, E
    Burris, H
    Douillard, JY
    Coxon, FY
    Maughan, T
    Bertetto, O
    Schueller, J
    Husseini, F
    Marschner, N
    Scheithauer, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 303S - 303S
  • [45] CARDIOTOXICITY OF 5-FU DURING ADJUVANT CHEMOTHERAPY IN CANCER OF COLON
    BUGNON, PY
    ELHAGE, A
    BOUNOUA, F
    GAUTIERBENOIT, C
    BULLETIN DU CANCER, 1992, 79 (04) : 365 - 367
  • [46] Economic evaluation of adjuvant chemotherapy in Stage III (SIII) colon cancer: Capecitabine versus 5FU/LV.
    Virik, K.
    Skedgel, C.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 312S - 312S
  • [47] Maspin expression in colorectal cancer correlates with microsatellite instability and is a predictor of survival benefit from adjuvant 5-FU treatment in stage III colon cancer
    不详
    PATHOLOGY RESEARCH AND PRACTICE, 2005, 201 (03) : 165 - 166
  • [48] Innovative chemotherapies for stage III colon cancer: A cost-effectiveness study
    Koperna, T
    Semmler, D
    HEPATO-GASTROENTEROLOGY, 2003, 50 (54) : 1903 - 1909
  • [49] Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa
    Tan, Sarah Xinhui
    Pumpalova, Yoanna
    Rogers, Alexandra M. M.
    Bhatt, Kishan
    Herbst, Candice-lee
    Ruff, Paul
    Neugut, Alfred I. I.
    Hur, Chin
    CANCER MEDICINE, 2023, 12 (14): : 15515 - 15529
  • [50] Cost analysis of capecitabine versus 5-FU/LV for colorectal cancer patients in the Netherlands
    Postma, MJ
    van Hartskamp, D
    Jansman, FG
    Willemse, PH
    Brouwers, JR
    VALUE IN HEALTH, 2002, 5 (06) : 540 - 540
12345